Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome.
Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.
Sawara
Y
Y
Department of Medicine, Kidney Center, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Itabashi
M
M
Kojima
C
C
Tabata
H
H
Kamei
D
D
Kawanishi
K
K
Moriyama
T
T
Sugiura
H
H
Tsukada
M
M
Takei
T
T
Ogawa
T
T
Yoshida
T
T
Arai
J
J
Uchida
K
K
Tsuchiya
K
K
Nitta
K
K
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D009402:Nephrosis, Lipoid / Q000188:drug therapy*; D012008:Recurrence; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab